Retinal Implants Market Size, Share & Industry Analysis, By Product Type (External-Camera-Encoded Retinal Prosthesis Systems, Implant-Integrated Photodetector Systems, and Projected-Light Photovoltaic Systems), By Technology (Wired/Trans-scleral Electrical Technology, Wireless RF/Inductive Technology, and Wireless Optical/Photovoltaic Technology), By Application (Age-Related Macular Degeneration, Retinitis Pigmentosa, and Other Retinal Disorders), By End User (Eye Hospitals & Retinal Specialty Centers, Academic & Teaching Medical Centers, and Others), and Regional Forecast, 2026-2034

The global retinal implants market size was valued at USD 0.85 million in 2025. The market is projected to grow from USD 4.25 million in 2026 to USD 185.00 million by 2034, exhibiting a CAGR of 60.30% during the forecast period.

Retinal implants are implantable neuroprosthetic systems developed to restore a degree of functional vision in patients whose photoreceptors have been severely damaged by retinal degeneration. Unlike conventional low-vision aids, these devices interact with surviving retinal cells and typically combine an implanted electrode or photovoltaic array with dedicated external components for image capture, processing, and power transfer. The market is gradually moving from long-running experimental development toward early commercialization as clinical evidence improves and wireless, photovoltaic, and miniaturized designs become more practical. The market growth is also supported by substantial unmet need in advanced retinal disorders, particularly geographic atrophy associated with age-related macular degeneration and inherited diseases such as retinitis pigmentosa. Recent regulatory progress, improving visual outcomes, renewed investor interest, and expansion of specialist implanting centers are collectively creating a clearer pathway for retinal neuroprostheses to move into routine clinical use.

Furthermore, Science Corporation, NIDEK CO., LTD., Bionic Vision Technologies Pty Ltd., and Shenzhen CAS-Envision Medical Technology Co., Ltd held the largest market share in 2025. The market expansion is driven by increased investments and strategic initiatives, including the launch of new products and partnerships.

RETINAL IMPLANTS MARKET TRENDS

Wireless Photovoltaic Implants and Smart-Glasses Integration to Reshape Product Development

Retinal prosthesis development is increasingly shifting toward wireless photovoltaic platforms that combine a small implanted component with sophisticated external wearable hardware. Earlier generation retinal prostheses frequently relied on implanted electronics, wired connections, or relatively complex power and signal-transmission architectures. Newer systems are seeking to reduce the amount of implanted hardware while moving image capture, image enhancement, magnification, and processing functions into external glasses. PRIMA reflects this technological direction. The system incorporates a subretinal photovoltaic implant with specialized glasses that project near-infrared visual information onto the implant, where it is converted into electrical stimulation. The external wearable also provides magnification functionality, allowing the system to enhance visual information before retinal stimulation.

• In July 2026, PRIMA received CE marking under the EU Medical Device Regulation and entered European commercial launch. This milestone is likely to reinforce investment in wireless power transfer, higher-density photovoltaic pixels, image-processing algorithms, smaller implant profiles, and more ergonomic wearable processors.

Over time, these developments could improve visual resolution, simplify hardware upgrades, and make retinal prostheses more practical for everyday activities.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Rising Unmet Need in Advanced Retinal Degeneration to Accelerate the Adoption of Retinal Prostheses

The soaring population of patients living with irreversible photoreceptor loss is emerging as a major factor driving retinal implants market growth. Advanced retinal diseases can progressively remove central or peripheral vision, while conventional treatments may slow disease progression without restoring vision that has already been lost. Retinal prostheses address this treatment gap by bypassing damaged photoreceptors and electrically activating surviving retinal pathways, creating the possibility of restoring useful visual information. The commercial opportunity is particularly significant in geographic atrophy associated with age-related macular degeneration, where the loss of central vision can severely affect reading, facial recognition, mobility, and independence. Confidence in this approach is strengthening with the availability of clinical evidence. According to a PRIMA clinical study published by the New England Journal of Medicine, 38 patients with geographic atrophy received the implant and 26 of the 32 participants assessed at 12 months achieved a clinically significant improvement in visual acuity. Science Corporation further estimates that AMD-associated geographic atrophy affects more than five million people globally. The increasing clinical validation of functional vision restoration is therefore expected to encourage physician referrals, patient acceptance, investment, and the development of implanting center infrastructure.

MARKET RESTRAINTS

Invasive Implantation and Reimbursement Uncertainty May Restrict Market Expansion

Despite encouraging progress, retinal implants remain highly specialized invasive devices, which can limit adoption among patients, physicians, hospitals, and payers. Implantation generally requires experienced vitreoretinal surgeons, sophisticated retinal imaging, careful eligibility assessment, post-operative monitoring, device programming, and visual rehabilitation. This creates a more complex care pathway than conventional ophthalmic medications or external visual aids and restricts treatment initially to a relatively small network of specialist institutions.

Safety is another consideration, particularly as many patients with advanced age-related macular degeneration are elderly and may have additional ocular or systemic conditions. According to a PRIMA clinical study published by the New England Journal of Medicine, 26 serious events were reported across 19 of the 38 implanted patients during the first 12 months. Most of these events occurred soon after surgery. 21 of the 26 events were reported within the first two months after implantation and 20 of those 21 events resolved within two months of onset. These findings indicate that retinal implantation requires careful post-surgical monitoring, particularly during the early recovery period. Regulatory approval can also result in a delay for commercial access. Although PRIMA received European CE marking in July 2026, Science Corporation reported that country-specific reimbursement applications and clinical-site activations were still underway. Until reimbursement pathways, physician training, and long-term safety evidence become more established, the product adoption is likely to remain concentrated in selected specialist centers.

MARKET OPPORTUNITIES

Expansion into Retinitis Pigmentosa and Other Retinal Disorders to Unlock New Patient Pools

The extension of retinal implant technology into additional photoreceptor-degenerative disorders represents a substantial long-term opportunity for manufacturers. The initial commercialization is being centered on advanced dry age-related macular degeneration, but the underlying neuroprosthetic principle may also be applicable to inherited retinal diseases where photoreceptors have deteriorated while downstream retinal pathways remain sufficiently functional. Retinitis pigmentosa and Stargardt disease are indications with significant opportunity potential as both can cause profound and progressive visual impairment and currently offer limited options for restoring lost vision.

In March 2026, Science Corporation raised USD 230 million in Series C financing to support PRIMA commercialization and expand its clinical program, including planned studies in retinitis pigmentosa and Stargardt disease. The company cited a prevalence of approximately 1 in 4,000 people for retinitis pigmentosa and 1 in 10,000 for Stargardt disease. If retinal implants gain approval for additional conditions such as retinitis pigmentosa or Stargardt disease, manufacturers would be able to serve more patients beyond the current focus on geographic atrophy. This would broaden the market opportunity, increase the number of patients treated at specialist centers, and reduce reliance on a single disease indication for future sales growth. It could also encourage new developers to invest in disease-specific implant designs and stimulation algorithms.

MARKET CHALLENGES

Building Scalable Implanting Networks and Commercial Access to Remain a Major Industry Challenge

One of the greatest challenges before retinal implant companies is converting clinical success into a scalable treatment pathway across multiple healthcare systems. A technically effective implant does not automatically translate into widespread adoption. Manufacturers must establish qualified surgical centers, train vitreoretinal surgeons, develop patient-screening protocols, provide technical and rehabilitation support, secure reimbursement, monitor long-term implant performance, and maintain tightly controlled manufacturing processes for highly specialized implantable electronics. These requirements create considerable fixed costs while early commercial procedure volumes remain relatively small. The rollout of PRIMA illustrates the difference between regulatory authorization and broad patient access. Although the system received CE marking in July 2026, authorizing commercial availability across 30 European countries, Science Corporation stated that reimbursement applications and clinical-site activations were still underway and that the first commercial implantation was expected in Germany. The company had also raised USD 230 million a few months earlier to support commercialization and further clinical development. For smaller retinal prosthesis developers, securing sufficient capital, specialist-center participation, manufacturing scale, and payer acceptance may prove difficult, potentially slowing market entry and geographical expansion.

Segmentation Analysis

By Product Type

Projected-Light Retinal Prosthesis Systems Segment Led the Market due to High Commercial Adoption

Based on product type, the market is segmented into external-camera–encoded retinal prosthesis systems, implant-integrated photodetector retinal prosthesis systems, projected-light photovoltaic retinal prosthesis systems, and others.

To know how our report can help streamline your business, Speak to Analyst

The projected-light photovoltaic retinal prosthesis systems segment accounted for a dominant market share in 2025 as this product type currently depicts the strongest track record from clinical validation to commercial adoption. These systems use specialized external glasses to deliver visual information and optical energy to a compact photovoltaic implant, reducing the dependence on bulky implanted electronics and wired connections.

The implant-integrated photodetector retinal prosthesis systems segment is projected to grow at a CAGR of 72.9% during the forecast period.

By Technology

Wireless Optical / Photovoltaic Prosthesis Technology Segment to Lead Considering the Shift toward Cable-free Architectures

By technology, the market is classified into wired / trans-scleral electrical prosthesis technology, wireless RF / inductive prosthesis technology, wireless optical / photovoltaic prosthesis technology, and hybrid & other wireless technologies.

The wireless optical / photovoltaic prosthesis technology segment is expected to hold the highest market share as retinal implant development shifts toward thinner, cable-free, and externally powered architectures. Photovoltaic implants can receive patterned optical signals from wearable glasses and convert those signals directly into electrical stimulation at the retinal interface, reducing the need for implanted batteries and extensive wiring. The segment is projected to hold a share of 57.4% in 2026.

The hybrid & other wireless technologies segment is estimated to grow at a CAGR of 72.7% during the forecast period.

By Application

Age-Related Macular Degeneration Segment to Dominate the Market due to Large Unmet Need in Geographic Atrophy

By application, the market is classified into age-related macular degeneration, retinitis pigmentosa, and other disorders.

The age-related macular degeneration segment is expected to account for the largest retinal implants market share owing to the substantial population affected by advanced geographic atrophy and the limited options available to restore vision once central photoreceptors are permanently lost. The combination of a sizeable patient pool, strong unmet treatment needs, mature clinical evidence, and early market access for treatment solutions supports the dominant share of the segment. Moreover, the segment is projected to hold a 66.1% share in 2026.

The retinitis pigmentosa segment is estimated to grow at a CAGR of 55.8% during the forecast period.

By End User

Eye Hospitals and Retina Speciality Centers Segment to Garner Major Share driven by Availability of Advanced Ophthalmic Infrastructure

Based on end user, the market is classified into eye hospitals & retina specialty centers, academic & teaching medical centers, and others.

The eye hospitals & retina specialty centers segment is expected to hold the highest market share given that retinal implantation requires capabilities that are concentrated in advanced ophthalmic institutions. Suitable and eligible patient selection depends on retinal imaging, residual-vision assessment, detailed ocular evaluation, and experienced vitreoretinal surgeons, while implantation must be followed by device programming, rehabilitation, and long-term clinical monitoring. Furthermore, the segment is set to hold a 65.7% share in 2026.

The academic & teaching medical centers segment is projected to grow at a CAGR of 57.8% during the forecast period.

Retinal Implants Market Regional Outlook

Based on geography, the market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the largest market share in 2024, with a value of USD 0.39 million, and hit a value of USD 0.36 million in 2025. The regional market is expected to expand significantly over the forecast period, primarily supported by the U.S.'s strong neurotechnology ecosystem, established vitreoretinal surgical infrastructure, high healthcare expenditure, and substantial population affected by advanced retinal degeneration. The availability of leading academic ophthalmology centers, experienced retinal surgeons, sophisticated retinal imaging infrastructure, and relatively high capacity to adopt premium implantable technologies are supporting regional market expansion.

U.S. Retinal Implants Market

In 2026, the U.S. market is estimated to reach USD 0.79 million, capturing 18.6% of the global revenue.

Europe

The Europe market is expected to exhibit a CAGR of 48.2% over the forecast period, the second-highest globally, reaching USD 2.47 million by 2026. Europe is expected to remain one of the significant regional markets, largely owing to its first-mover advantage in the commercialization of next-generation photovoltaic retinal prostheses. The region also has a strong foundation of specialist retinal centers and academic hospitals that participated in the pivotal PRIMAvera clinical program across several European countries.

U.K. Retinal Implants Market

The U.K. market is projected to reach USD 0.39 million by 2026, accounting for 9.2% of the global market revenue.

Germany Retinal Implants Market

The Germany market is estimated to reach about USD 0.52 million by 2026, representing roughly 12.2% of global revenue.

Asia Pacific

In 2026, the Asia Pacific market is predicted to reach USD 0.64 million, ranking as the third-largest globally. The regional market is expected to record strong growth as the region combines a large potential patient population with an increasingly active retinal-prosthesis research and clinical development ecosystem. In parallel, China and other Asian markets are seeing greater investment in ophthalmic technology, specialist hospitals, advanced retinal imaging, and domestic medical device innovation.

Japan Retinal Implants Market

The Japan market is projected to generate approximately USD 0.18 million in revenue by 2026, contributing nearly 4.2% to the global market.

China Retinal Implants Market

The China market is anticipated to reach approximately USD 0.13 million by 2026, contributing about 3.0% to global revenues.

India Retinal Implants Market

The India market is estimated to touch approximately USD 0.05 million by 2026, corresponding to about 1.3% of global revenues.

Latin America and Middle East & Africa

Latin America and the Middle East & Africa markets are anticipated to witness moderate market growth, with Latin America expected to reach around USD 0.17 million by 2026. The Latin America market is expected to grow as advanced ophthalmic care expands across major markets such as Brazil and Mexico. The region currently represents a comparatively early-stage opportunity given that commercially available retinal prostheses remain limited and access to highly specialized vitreoretinal surgery is concentrated in major urban and academic centers.

The Middle East & Africa market is expected to grow from a relatively small base, with adoption initially concentrated in the GCC and a limited number of advanced ophthalmology centers in South Africa and other major urban markets. Continued investment in tertiary healthcare infrastructure, establishment of specialist eye hospitals, increasing access to vitreoretinal surgery, and government initiatives aimed at introducing advanced medical technologies are supporting the regional market expansion.

GCC Retinal Implants Market

By 2026, the GCC market is expected to generate approximately USD 0.05 million, accounting for nearly 1.2% of global revenues.

COMPETITIVE LANDSCAPE

Key Industry Players

Major Players to Strengthen their Competitive Edge with Focus on Technology Architecture and Implant Performance

The global retinal implants market is highly concentrated and still at an early stage of commercialization, with competition driven more by clinical maturity, regulatory progress, implant performance, and technology architecture than by traditional volume-based market share. Science Corporation currently holds the strongest commercial position through PRIMA. The company acquired Pixium Vision’s PRIMA assets in 2024 and subsequently advanced the platform toward commercialization.

Other companies, including NIDEK and Bionic Vision Technologies, remain important clinical-stage competitors developing alternative retinal prosthesis approaches, such as suprachoroidal stimulation systems.

Competitive differentiation is therefore centered on visual acuity improvement, implant miniaturization, wireless power delivery, surgical simplicity, long-term safety, indication expansion, and reimbursement readiness. Over the forecast period, new clinical entrants and technology partnerships are expected to gradually broaden competition, although high R&D costs and demanding regulatory requirements are likely to maintain relatively high barriers to entry.

LIST OF KEY RETINAL IMPLANTS COMPANIES PROFILED

• Science Corporation (U.S.)
• NIDEK CO., LTD. (Japan)
• Bionic Vision Technologies Pty Ltd. (Australia)
• Shenzhen CAS-Envision Medical Technology Co., Ltd. (China)
• IntelliMicro Medical Co., Ltd. (China)
• Iridium Medical Technology Co., Ltd. (Taiwan)
• SIBIONICS (China)
• Bionic Eye Technologies, Inc. (U.S.)
• Nanovision Biosciences, Inc. (U.S.)
• Golden Eye Bionics, LLC (U.S.)

KEY INDUSTRY DEVELOPMENTS

• July 2026: Science Corporation received CE marking under the EU Medical Device Regulation for PRIMA and announced its European commercial launch.
• July 2026: The FDA granted PRIMA two Humanitarian Use Device (HUD) designations. One was granted for an orphan subset of patients blinded by advanced geographic atrophy secondary to AMD and another was awarded for vision loss caused by Stargardt disease.
• May 2026: LambdaVision partnered with Helogen Corporation for an orbital manufacturing mission involving its artificial-retina protein. The program is intended to validate autonomous, traceable, and GMP-oriented manufacturing processes for future scalable production of the implant.
• May 2026: Japan's clinical-trial registry recorded the OUReP001 investigator-initiated trial, evaluating subretinal implantation of OUH-MU001 using the OUH-MU Injector in patients with retinitis pigmentosa.
• March 2026: Science Corporation closed a USD 230 million Series C financing, bringing the total capital invested since its founding to approximately USD 490 million. The funding is intended to support PRIMA commercialization and expansion into retinitis pigmentosa and Stargardt disease, with initial expansion studies planned at Sydney Eye Hospital.

REPORT COVERAGE

The global retinal implants market report provides an in-depth analysis of the market based on various segments and highlights key trends, opportunities, restraints, and challenges. It also provides insights into technological advancements, key industry developments, company market share analysis, and the profiles of leading companies. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth and advancement of the market over recent years.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation

Research Methodology

1. Bottom Up Approaches

Approach 1: Revenues and Market Share of Major Players

• Collection of retinal implant-specific revenues from company filings, presentations, product disclosures, and commercial updates
• Estimation of company shares based on product availability, implant volumes, geographical presence, regulatory status, and commercialization stage
• Triangulation of company revenues to derive the global market estimate.

Approach 2: Implant Volume & ASP Analysis

• Estimation of commercial retinal implantation volumes across major countries and implanting centers
• Analysis of manufacturer ASPs for retinal prosthesis systems and dedicated components
• Implant volumes × manufacturer ASP used to estimate country and regional market size.

Approach 3: Eligible Patient Population Model

• Assessment of diagnosed and treatment-eligible patients with AMD, retinitis pigmentosa, and other qualifying retinal disorders
• Application of clinical eligibility, treatment penetration, patient acceptance, and regulatory-access assumptions
• Eligible treated patients × implant utilization × ASP used to validate market size.

2. Top Down Approaches

Approach 1: Ophthalmology & Neuroprosthetic Device Market Analysis

• Analysis of ophthalmic medical-device spending, advanced retinal treatment expenditure, and implantable neuroprosthetic device adoption across major countries
• Estimation of the proportion attributable specifically to retinal implants
• Regional estimates were reconciled with bottom-up company, patient, and procedure-based calculations.

3. List of Key Sources

Secondary Sources

• FDA, European Commission/EUDAMED, PMDA, NMPA, CDSCO, TGA
• WHO, OECD, World Bank, Eurostat
• AAO, ASRS, EURETINA, ARVO, Retina International
• gov and WHO ICTRP
• Company annual reports, regulatory filings, investor presentations, clinical updates, product launches, approvals, and commercial announcements.

4. Primary Interviews

Supply Side Interviews: 60%

• Discussions with retinal implant developers, medical device companies, distributors, suppliers, sales executives, product managers, and industry experts to validate pricing, commercial adoption, competitive positioning, and market growth.

Demand Side Interviews: 40%

• Discussions with vitreoretinal surgeons, ophthalmologists, eye hospitals, retina specialty centers, academic medical centers, and procurement professionals to assess patient eligibility, implant utilization, adoption barriers, reimbursement, and treatment preferences.